|
The Neuroprotective Effect of Trimetazidine in Rats’ Model of Alzheimer's disease
|
|
| Author:
|
HEBAH MAJED HAMOOD, ADEEB A. AL-ZUBAIDY
|
| Abstract:
|
Alzheimer's disease is a progressive disease, and it is characterized by gradual loss of memory and cognitive functions that can occur at any age; however, it's most common among the elderly. Trimetazidine (TMZ) is an anti-ischemic agent that had been reported to have antioxidant effect. The preset study was designed to study the effect of trimetazidine in lipoploysacchride - induced Alzheimer's disease - like features in rats. Rats were divided equally (7 rats/group) into five groups; control group, induction group (rats were administered lipoploysacchride 250 µg/kg i.p. once daily for 7 days), and the further three treatment groups included rats received tested drugs prophylactically for 21 days then the induction done by lipoplysacchride (250 µg/kg) i.p. once daily together with continuation of the same oral doses of the tested drugs for further 7days; these treatment groups included donepezil group (donepezil 0.5 mg/Kg orally once daily), trimetazidine group ( trimetazidine 25mg/Kg orally twice daily) and combination group (donepezil 0.5mg/Kg and trimetazidine 25mg/Kg; both were administrated orally once daily).Behavioral parameters like Ymaze maze,and Novel Object Recognition, were evaluated. Oxidative stress parameters and inflammatory cytokines were carried out in the sample of brain tissues. The present study revealed the neuroprotective effect of trimetazidine against lipopolysacchride-induced Alzheimer's disease-like features in rats. Such beneficial effect seemed probably due to trimetazidine significant antioxidant and anti-inflammatory effects as been proved in the present study.
|
| Keyword:
|
Alzheimer's disease, lipopolysaccharide, donepezil, Trimetazidine, Rats
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP1.208
|
| Download:
|
Request For Article
|
|
|